Nykode Therapeutics Presents AI-Powered Immunotherapy Design Capabilities at BioPharma Drug Discovery Nexus 2026

• Nykode showcases proprietary machine learning platform for multi-antigen immunotherapy optimization at leading industry conference in Zurich

Oslo, Norway, April 30, 2026 – Nykode Therapeutics ASA (OSE: NYKD), a clinical stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, today presents its proprietary artificial intelligence (AI) capabilities at the 25th BioPharma Drug Discovery Nexus conference, taking place in Zurich, Switzerland on 29–30 April 2026.

Nykode Therapeutics will deliver a presentation titled "From Precision to Performance: AI-Powered Strategies for Optimal Immunotherapies Design", highlighting how the Company is leveraging AI and machine learning (ML) to accelerate and enhance its immunotherapy discovery pipeline. Key highlights from the presentation include:

• Predictive design modelling: Nykode has developed AI capabilities that enable the Company to model the impact of immunotherapy design choices on protein integrity, folding, and cellular secretion prior to laboratory experimentation, materially reducing time and resource requirements in early-stage discovery

• Large-scale construct evaluation: Nykode’s proprietary ML models support the simultaneous evaluation of thousands of multi-antigen immunotherapy constructs, systematically prioritising candidate designs against defined criteria for immunogenicity and biophysical properties.

• Interpretable AI: Nykode develops proprietary models and runs them alongside interpretable models, enabling scientists to understand the molecular features driving optimal design selection and apply informed scientific judgment at each stage of the pipeline.

• Human-on-the-loop philosophy: Nykode operates a human-on-the-loop framework in which AI serves to augment rather than replace scientific expertise, with qualified oversight embedded throughout the discovery and development process

“At Nykode, applying AI to immunotherapy design is not new as it has been central to how we have built and refined our platform for years. Today's presentation reflects how deeply embedded these capabilities have become in the way we work. Our machine learning models allow us to make smarter, faster decisions about which immunotherapy candidates to advance and, crucially, our scientists understand and trust the outputs because interpretability is built into our approach from the start. We believe this combination of longstanding AI capability and human oversight is what distinguishes a truly effective AI-driven discovery process,” said Michael Engsig, Chief Executive Officer at Nykode Therapeutics.

The presentation will be available after the session at the Company’s Webpage: https://nykode.com/research-and-development/scientific-papers-and-presentations/

About Nykode Therapeutics Nykode Therapeutics is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies with a focus on the treatment of cancer and autoimmune diseases. Nykode’s modular immunotherapy technology specifically targets antigens to antigen presenting cells (APC), which have been shown to induce a broad, strong and long-lasting antigen specific immune response in cancer, which correlates with clinical responses.

Nykode’s lead product candidates are abi-suva, a therapeutic immunotherapy for the treatment of HPV16 induced malignancies which demonstrated favorable safety and efficacy results from its Phase 2 trial for the treatment of late-line r/m cervical cancer. Abi-suva is currently being further developed in first line head and neck cancer with the randomized Abili-T trial with interim results within 2027.

VB10.NEO, an individualized cancer neoantigen immunotherapy, has been investigated in two trials with more than 10 different indications. Nykode is also utilizing its APC-targeted technology to create an immune tolerance platform for the potential use in autoimmune disorders, organ transplant rejections, anti-drug antibody reactions and allergy.

Nykode Therapeutics’ shares are traded on the Oslo Stock Exchange (OSE: NYKD). Further information about Nykode Therapeutics can be found at http://www.nykode.com.

Forward-looking statements for Nykode Therapeutics This announcement and any materials distributed in connection with this announcement may contain certain forward-looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect the company's current expectations and assumptions as to future events and circumstances that may not prove accurate. A number of material factors could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements.

Contact for Nykode Therapeutics ASA: IR@nykode.com Nykode Therapeutics ASA Oslo Science Park Gaustadalléen 21 N-0349 Oslo, Norway